Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,061 | 127 | 911 |
| Samples | 334 | 61 | 264 |
| Peptides | 280 | 50 | 228 |
Function
STIM1 · Stromal interaction molecule 1
This gene encodes a type 1 transmembrane protein that mediates Ca2+ influx after depletion of intracellular Ca2+ stores by gating of store-operated Ca2+ influx channels (SOCs). It is one of several genes located in the imprinted gene domain of 11p15.5, an important tumor-suppressor gene region. Alterations in this region have been associated with the Beckwith-Wiedemann syndrome, Wilms tumor, rhabdomyosarcoma, adrenocrotical carcinoma, and lung, ovarian, and breast cancer. This gene may play a role in malignancies and disease that involve this region, as well as early hematopoiesis, by mediating attachment to stromal cells. Mutations in this gene are associated with fatal classic Kaposi sarcoma, immunodeficiency due to defects in store-operated calcium entry (SOCE) in fibroblasts, ectodermal dysplasia and tubular aggregate myopathy. This gene is oriented in a head-to-tail configuration with the ribonucleotide reductase 1 gene (RRM1), with the 3' end of this gene situated 1.6 kb from the 5' end of the RRM1 gene. Alternative splicing of this gene results in multiple transcript variants. [provided by RefSeq, May 2013].
Isoforms & Proteins
6 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 229 amino-acid changes on canonical ENST00000300737 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in STIM1 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in STIM1 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 5/40 12% | 0/0 0% |
| Acute Myeloid Leukemia | 2/90 2% | 0/0 0% |
| Endometrial Carcinoma | 2/42 5% | 10/612 2% |
| Melanoma | 5/210 2% | 32/1899 2% |
| Germ Cell Tumour | 1/25 4% | 2/169 1% |
| Colorectal Carcinoma | 8/143 6% | 44/3239 1% |
| Gastric Carcinoma | 3/74 4% | 23/1809 1% |
| Biliary Tract Carcinoma | 0/54 0% | 12/950 1% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 8/810 1% |
| Non-Small Cell Lung Carcinoma | 6/304 2% | 11/1390 1% |
| Esophageal Squamous Cell Carcinoma | 4/51 8% | 22/2550 1% |
| Burkitts Lymphoma | 2/32 6% | 0/196 0% |
| Other Solid Cancers | 0/94 0% | 14/1515 1% |
| Adrenocortical Carcinoma | 0/3 0% | 1/112 1% |
| Glioma | 3/52 6% | 15/2127 1% |
| Esophageal Carcinoma | 2/23 9% | 4/769 1% |
| Cervical Carcinoma | 1/35 3% | 2/422 0% |
| Ovarian Carcinoma | 4/109 4% | 3/998 0% |
| Ewings Sarcoma | 2/63 3% | 0/262 0% |
| Non-Cancerous | 0/104 0% | 5/830 1% |
| Hepatocellular Carcinoma | 0/46 0% | 12/2210 1% |
| Bladder Carcinoma | 2/58 3% | 3/956 0% |
| Rhabdomyosarcoma | 0/33 0% | 1/171 1% |
| Mesothelioma | 1/62 2% | 0/165 0% |
| Wilms Tumour | 0/5 0% | 2/474 0% |
| Other Sarcomas | 0/69 0% | 3/699 0% |
| Small Cell Lung Carcinoma | 1/9 11% | 2/752 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 6/1592 0% |
| Breast Carcinoma | 0/144 0% | 12/3264 0% |
| Head and Neck Carcinoma | 0/85 0% | 5/1574 0% |
Mutation Distribution
Where STIM1 is mutated · all tissues, split by cell line vs tissue
How many mutations in STIM1 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,061 mutations in STIM1
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|